A phase 3 trial of seladelpar in primary biliary cholangitis

GM Hirschfield, CL Bowlus, MJ Mayo… - … England Journal of …, 2024 - Mass Medical Soc
Background Effective treatments for patients with primary biliary cholangitis are limited.
Seladelpar, a peroxisome proliferator–activated receptor delta agonist, has potential …
被引用次数：37 相关文章

A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis

GM Hirschfield, CL Bowlus, MJ Mayo… - The New England …, 2024 - pubmed.ncbi.nlm.nih.gov
Background Effective treatments for patients with primary biliary cholangitis are limited.
Seladelpar, a peroxisome proliferator-activated receptor delta agonist, has potential …

A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis

G Hirschfield, C Bowlus, M Mayo, A Kremer… - THE NEW ENGLAND …, 2024 - iris.unipa.it
Background Effective treatments for patients with primary biliary cholangitis are limited.
Seladelpar, a peroxisome proliferator-activated receptor delta agonist, has potential …

A phase 3 trial of seladelpar in primary biliary cholangitis

GM Hirschfield, CL Bowlus, MJ Mayo, AE Kremer… - 2024 - acikerisim.erdogan.edu.tr
Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a
peroxisome proliferator–activated receptor delta agonist, has potential benefits. METHODS …

A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.

GM Hirschfield, CL Bowlus, MJ Mayo… - The New England …, 2024 - europepmc.org
Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a
peroxisome proliferator-activated receptor delta agonist, has potential benefits. In this phase …

A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis

RESPONSE Study Group - … England Journal of …, 2024 - providence.elsevierpure.com
Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a
peroxisome proliferator–activated receptor delta agonist, has potential benefits. METHODS …

A phase 3 trial of seladelpar in primary biliary cholangitis

GM Hirschfield, CL Bowlus, MJ Mayo, AE Kremer… - 2024 - 79.123.160.167
Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a
peroxisome proliferator–activated receptor delta agonist, has potential benefits. METHODS …

A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis

RESPONSE study group - New England …, 2024 - utsouthwestern.elsevierpure.com
Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a
peroxisome proliferator–activated receptor delta agonist, has potential benefits. METHODS …